ODYSSEA PHARMA
ActiveODYSSEA PHARMA has been active since 2007 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €76.39M and a net result of €35.85M. Equity is growing by ~35.2% per year across the filed fiscal years. Its solvency ranks better than 83% of 64 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
84
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100▲+4
Solvency100=
Growth84▲+9
Track record100
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2M at 30 days acceptable
Liquidity ample (current ratio 5.26 against 3.5 in 2024; short-term debt: 16.1% and cash: 0% of total assets), and 16.1% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
83.9%
Return on assets
39.4%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Sector 21
higher
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
28 d early
2024
8 d early
2023
13 d early
2022
9 d late
2021
25 d early
2020
5 d early
2019
on the day
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
€76.16M▲ 75.5%
2024 · €43.39M
2018: €23.00M
2019: €35.72M
2020: €48.65M
2021: €51.48M
2022: €41.90M
2023: €35.32M
2024: €43.39M
2018 → 2025
EBIT margin
52.5%▲ 27.5pp
2024 · 25.0%
2018: -59.7%
2019: -21.3%
2020: 9.4%
2021: 2.2%
2022: 10.8%
2023: 0.8%
2024: 25.0%
2018 → 2025
Net result
€35.85M▲ 221%
2024 · €11.18M
2018: €-13.93M
2019: €-7.88M
2020: €5.17M
2021: €11.45M
2022: €15.99M
2023: €-3.40M
2024: €11.18M
2018 → 2025
Working capital
€62.25M▲ 146%
2024 · €25.32M
2018: €7.29M
2019: €-59.01M
2020: €-38.61M
2021: €-10.80M
2022: €10.14M
2023: €13.51M
2024: €25.32M
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Turnover€51.48M-€41.90M▼ 18.6%€35.32M▼ 15.7%€43.39M▲ 22.9%€76.16M▲ 75.5%
Equity€16.77M-€32.76M▲ 95.3%€29.36M▼ 10.4%€40.54M▲ 38.1%€76.39M▲ 88.4%
Operating result€1.12M-€4.53M▲ 303%€278k▼ 93.9%€10.83M▲ 3,799%€39.97M▲ 269%
Net result€11.45M-€15.99M▲ 39.6%€-3.40M€11.18M€35.85M▲ 221%
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 269% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €91.00M
Fixed assets
€14.14M▼ 7.1%
Current assets
€76.86M▲ 117%
Equity and liabilities €91.00M
Equity
€76.39M▲ 88.4%
Debt
€14.61M▲ 44.4%
The debt ratio falls from 20.0% to 16.1%. Equity and debt are higher.
Key figures and ratios
EBITDA
€42.82M▲
2024 · €13.45M
Cash flow
€38.70M▲
2024 · €13.80M
Solvency
83.9%▲
2024 · 80.0%
Current ratio
5.26▲
2024 · 3.50
Quick ratio
4.81▲
2024 · 2.71
Debt / equity
0.19▼
2024 · 0.25
ROE
46.9%▲
2024 · 27.6%
ROA
39.4%▲
2024 · 22.1%
Interest coverage
898.87
Debt
€14.61M▲
2024 · €10.12M
Debt ≤ 1 year
€14.61M▲
2024 · €10.12M
Income taxes
€2.87M▲
2024 · €1.46M
Staff costs
€6.59M▲
2024 · €5.87M
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€50.66M€91.00M▲
Fixed assets21/28€15.21M€14.14M▼
Intangible fixed assets21€3.37M€2.49M▼
Tangible fixed assets22/27€11.84M€11.65M▼
Land and buildings22€7.55M€7.72M▲
Plant, machinery and equipment23€1.10M€848k▼
Furniture and vehicles24€135k€531k▲
Assets under construction and advance payments27€3.06M€2.55M▼
Current assets29/58€35.45M€76.86M▲
Stocks and contracts in progress3€7.99M€6.63M▼
Stocks30/36€7.95M€6.63M▼
Raw materials and consumables30/31€5.80M€5.10M▼
Work in progress32€572k€956k▲
Finished goods33€1.58M€577k▼
Contracts in progress37€35k-
Amounts receivable within one year40/41€27.46M€70.23M▲
Trade receivables40€9.44M€16.27M▲
Other amounts receivable41€18.02M€53.96M▲
Cash at bank and in hand54/58€0€0=
Equity and liabilities
Total equity and liabilities10/49€50.66M€91.00M▲
Equity10/15€40.54M€76.39M▲
Contributions10/11€90.15M€90.15M=
Profit (loss) carried forward14€-49.61M€-13.76M▲
Amounts payable17/49€10.12M€14.61M▲
Amounts payable within one year42/48€10.12M€14.61M▲
Trade debts44€8.67M€11.48M▲
Suppliers440/4€8.67M€11.48M▲
Taxes, remuneration and social security45€1.45M€3.14M▲
Taxes450/3€546k€2.05M▲
Remuneration and social security454/9€905k€1.09M▲
Income statement
Code20242025
Operating income70/76A€43.68M€75.45M▲
Turnover70€43.39M€76.16M▲
Change in stocks of work in progress, finished goods and contracts in progress71€174k€-715k▼
Other operating income74€115k€8k▼
Operating charges60/66A€32.85M€35.49M▲
Goods for resale, raw materials and consumables60€3.68M€4.91M▲
Purchases600/8€1.94M€4.59M▲
Change in stocks: decrease (increase)609€1.74M€316k▼
Services and other goods61€20.68M€21.00M▲
Remuneration, social security and pensions62€5.87M€6.59M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2.62M€2.85M▲
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€-22k€123k▲
Other operating charges640/8€28k€23k▼
Operating profit (loss)9901€10.83M€39.97M▲
Financial income75/76B€1.81M€739k▼
Recurring financial income75€1.81M€739k▼
Income from current assets751€45k€739k▲
Other financial income752/9€1.77M-
Financial charges65/66B-€1.99M
Recurring financial charges65-€1.99M
Debt charges650-€48k
Other financial charges652/9-€1.94M
Profit (loss) for the period before taxes9903€12.65M€38.72M▲
Income taxes67/77€1.46M€2.87M▲
Taxes670/3€1.46M€2.87M▲
Profit (loss) for the period9904€11.18M€35.85M▲
Profit (loss) for the period to be appropriated9905€11.18M€35.85M▲
Appropriation of the result
Profit (loss) to be appropriated9906€-49.61M€-13.76M▲
Profit (loss) brought forward from the previous period14P€-60.79M€-49.61M▲
Social balance
Average headcount (FTE)908759.062.4▲
The notes to these accounts (61 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
03-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial
Highest result since 2018net €35.85M ▲221%
Operating result €39.97M, net result €35.85M, both a record.
31-12
Financial
Equity above €50MEq €76.39M ▲88.4%
2 profitable years in a row build equity to €76.39M.
23-07
NBB filing
Annual accounts filed
fiscal year 2024 · unclassified schema
2024
31-12
Financial
Back to profitnet €11.18M
Net result €11.18M after one loss-making year.
31-12
Financial
Liquidity doublescurrent ratio 3.50
Current ratio from 1.58 to 3.50; short-term debt falls from €23.13M to €10.12M.
18-07
NBB filing
Annual accounts filed
fiscal year 2023 · unclassified schema
10-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 9 days late
2023
09-08
NBB filing
Annual accounts filed
fiscal year 2022 · unclassified schema · 9 days late
2022
31-12
Financial
Liquidity quadruplescurrent ratio 2.38
Current ratio from 0.55 to 2.38; short-term debt falls from €24.02M to €7.35M.
31-12
Financial
Equity above €25MEq €32.76M ▲95.3%
3 profitable years in a row build equity to €32.76M.
06-07
NBB filing
Annual accounts filed
fiscal year 2021 · unclassified schema
2021
31-12
Financial
Equity above €10MEq €16.77M ▲212%
2 profitable years in a row build equity to €16.77M.
26-07
NBB filing
Annual accounts filed
fiscal year 2020 · unclassified schema
2020
31-12
Financial
Back to profitnet €5.17M
Net result €5.17M after 2 loss-making years.
31-12
Financial
Equity above €5MEq €5.37M ▲1406%
Equity rises from €357k to €5.37M.
31-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
22-07
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
27-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
26 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Grâce-Hollogne · 1 establishment unit since 2007
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue du Travail 164460 Grâce-HollogneGround area
7,769 m²
Building footprint
2,744 m²
Volume, LiDAR
22,440 m³
Parcel 62046A0026/02_000, Wallonia · tallest building 10.1 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
ODYSSEA PHARMA
since 20072.165.409.984
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62046A0026/02_000 | Wallonia | 7,769 m² | 1 · 2,744 m² | 10.1 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHYSIOL
BE 0428.242.033
Liège · Eq €78.44M
Novo Nordisk Production Belgium SA
BE 0465.935.738
Brussel · Eq €74.22M
BAXTER
BE 0403.093.693
Lessines · Eq €83.81M
ROCHE
BE 0403.088.151
Anderlecht · Eq €64.46M
LONZA VERVIERS
BE 0463.156.786
Verviers · Eq €62.40M
Of 149 companies in sector 21201 we hold annual accounts for 116. 34 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded18-09-2007
Fiscal year end31-12
Activities, NACEBEL
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
Sources
Crossroads Bank for EnterprisesNational Bank · 19 filingsAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.